Pre-Market Technical Scan on Biotech Equities -- Pluristem Therapeutics, Ritter Pharma, Ignyta, and Tenax Therapeutics

Wednesday, November 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 29, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information

WallStEquities.com has issued free tailored Stock Review on PSTI, RTTR, RXDX, and TENX which is a click away at www.wallstequities.com/registration. On Tuesday, November 28, 2017, US markets saw broad based gains with
all sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,912.36, up 0.49%; the Dow Jones Industrial Average edged 1.09% higher, to finish at 23,836.71; and the S&P 500 closed at 2,627.04, up 0.98%. This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Ritter Pharmaceuticals Inc. (NASDAQ: RTTR), Ignyta Inc. (NASDAQ: RXDX), and Tenax Therapeutics Inc. (NASDAQ: TENX). Get your free stock reports on these stocks by registering now on Wall St. Equities at: www.wallstequities.com/registration

Pluristem TherapeuticsOn Tuesday, shares in Haifa, Israel-based Pluristem Therapeutics Inc. recorded a trading volume of 219,314 shares. The stock ended the session 3.80% lower at $1.52. The Company's shares have gained 27.73% over the previous three months. The stock is trading above its 200-day moving average by 12.30%. Moreover, shares of Pluristem Therapeutics, which together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel, have a Relative Strength Index (RSI) of 47.53. Get started with a complimentary subscription and access to the free report on PSTI at: www.wallstequities.com/registration/?symbol=PSTI

Ritter PharmaceuticalsLos Angeles, California headquartered Ritter Pharmaceuticals Inc.'s stock closed the day 5.13% lower at $0.33 with a total trading volume of 548,105 shares. The stock is trading below its 50-day moving average by 13.85%. Additionally, shares of Ritter Pharma, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, have an RSI of 44.00. Free research on RTTR can be accessed at: www.wallstequities.com/registration/?symbol=RTTR

IgnytaShares in San Diego, California headquartered Ignyta Inc. recorded a trading volume of 728,691 shares. The stock ended yesterday's trading session 2.12% higher at $16.85. The Company's shares have advanced 68.50% over the previous three months, 155.30% in the past twelve months, and 217.92% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.86% and 63.11%, respectively. Furthermore, shares of Ignyta, which engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases, have an RSI of 66.99. Sign up today for the free research report on RXDX at: www.wallstequities.com/registration/?symbol=RXDX

Tenax TherapeuticsMorrisville, North Carolina headquartered Tenax Therapeutics Inc.'s stock finished Tuesday's session 1.32% higher at $0.41 with a total trading volume of 919,205 shares, which was above their three months average volume of 512.90 thousand shares. The Company's shares have advanced 22.74% over the previous three months. The stock is trading below its 50-day moving average by 1.52%. Additionally, shares of Tenax Therapeutics, which focuses on the identification, development, and commercialization of a portfolio of products for the critical care market in the US and Canada, have an RSI of 49.62. Wall St. Equities' research coverage also includes the downloadable free report on TENX at: www.wallstequities.com/registration/?symbol=TENX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----pluristem-therapeutics-ritter-pharma-ignyta-and-tenax-therapeutics-300563498.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store